中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 9
Sep.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(9): 1790-1795

Establishment of a noninvasive diagnostic model for chronic hepatitis B liver fibrosis patients with normal aminotransferases aged ≤30 years

DOI: 10.12449/JCH240912
  • 1.

    Department of Infectious Diseases，The First Hospital of Changsha，Changsha 410000，China

  • 2.

    Second Department of Liver Diseases，Shenzhen Third People’s Hospital，Shenzhen，Guangdong 518112，China

Research funding:

Key Discipline Construction Project of Shenzhen (SZXK076)

More Information
  • Corresponding author: WANG Fang， 807874297@qq.com （ORCID： 0009-0003-0092-3403）; LU Jin， 2276984@qq.com （ORCID： 0000-0003-0035-1890）
  • Received Date: 2024-01-29
  • Accepted Date: 2024-03-18
  • Published Date: 2024-09-25
    Abstract
  •   Objective  To establish a noninvasive diagnostic model for liver fibrosis in chronic hepatitis B （CHB） patients with normal alanine aminotransferase （ALT） and an age of ≤30 years by selecting specific indicators from the commonly used noninvasive indicators such as clinical， biochemical， and imaging indicators， to avoid invasive liver biopsy in such patients to some extent， and to guide the timing of antiviral therapy.  Methods  A total of 251 CHB patients with normal ALT and an age of ≤30 years who underwent liver biopsy in Shenzhen Third People’s Hospital and The First Hospital of Changsha from January 2019 to January 2022 were enrolled， with 175 patients in the model group and 76 patients in the validation group， and commonly used clinical indicators were obtained based on clinical experience and related articles. The two-independent-samples t test or the two-independent-samples Mann-Whitney U rank sum test was used for comparison of continuous data between groups， and the chi-square test was used for comparison of categorical data between groups. A Spearman rank correlation analysis was used to investigate the correlation between each indicator and liver fibrosis and identify the indicators with correlation （P<0.01， r>0.200）； a Logistic regression analysis was used to establish a noninvasive diagnostic model， and the receiver operating characteristic （ROC） curve was used to evaluate its performance and perform validation of the model； this model was then compared with the widely used models of aspartate aminotransferase-to-platelet ratio index （APRI） and fibrosis-4 （FIB-4）. The Kappa consistency test was used to investigate the consistency of pathological results.  Results  A total of 17 commonly used clinical indicators were obtained， among which 9 indicators （ALT， aspartate aminotransferase ［AST］， gamma-glutamyl transpeptidase ［GGT］， ferritin ［FERR］， platelet count ［PLT］， procollagen type Ⅲ amino-terminal peptide ［PⅢP］， collagen Ⅳ ［CⅣ］， HBV DNA， and spleen thickness） were correlated with liver fibrosis （P<0.01， r>0.232）. Based on the above indicators， the predictive model was established as P=1/（1+e-γ）， γ=-1.902+0.106×AST－0.011×PLT－0.265×HBV DNA+0.059×PⅢP， in which P was the probability for predicting ≥S2 liver fibrosis and γ was the predictive index. The comparison between each indicator and the model showed that the model had the largest area under the ROC curve of 0.852， with a sensitivity of 92.7% and a specificity of 76.9%. The model was validated in 76 patients and showed an accuracy of 77.600%. The model was compared with APRI and FIB-4， and the results showed that the model has good accuracy.  Conclusion  Compared with the models of APRI and FIB-4 commonly used in the world， this model can more accurately judge the degree of liver fibrosis in such patients， thereby replacing liver biopsy to some extent and guiding the timing of antiviral therapy.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    Hepatology Branch of Chinese Medical Association, Infectious Diseases Branch of Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Chin J Infect Dis, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.
    [2]
    SONNEVELD MJ, BROUWER WP, CHAN HL, et al. Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: Results from the SONIC-B study[J]. Lancet Gastroenterol Hepatol, 2019, 4( 7): 538- 544. DOI: 10.1016/S2468-1253(19)30087-1.
    [3]
    ZHOU XL, WANG YB, LU W, et al. Value of five noninvasive serum models in the diagnosis of chronic hepatitis B liver fibrosis[J]. J Clin Hepatol, 2021, 37( 7): 1567- 1571. DOI: 10.3969/j.issn.1001-5256.2021.07.018.

    周新兰, 王雁冰, 陆伟, 等. 5种血清无创模型对慢性乙型肝炎肝纤维化分期诊断价值的比较[J]. 临床肝胆病杂志, 2021, 37( 7): 1567- 1571. DOI: 10.3969/j.issn.1001-5256.2021.07.018.
    [4]
    FATTOVICH G, BORTOLOTTI F, DONATO F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors[J]. J Hepatol, 2008, 48( 2): 335- 352. DOI: 10.1016/j.jhep.2007.11.011.
    [5]
    WU XJ, WANG Y, CHEN J, et al. Baseline predictors of virological response for chronic hepatitis B patients[J]. World J Gastroenterol, 2009, 15( 34): 4311- 4315. DOI: 10.3748/wjg.15.4311.
    [6]
    CAO W, CHEN HD, YU YW, et al. Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020[J]. Chin Med J, 2021, 134( 7): 783- 791. DOI: 10.1097/CM9.0000000000001474.
    [7]
    LIU J, ZHANG SK, WANG QM, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: A population-based, cross-sectional study[J]. Lancet Infect Dis, 2016, 16( 1): 80- 86. DOI: 10.1016/S1473-3099(15)00218-2.
    [8]
    LUO X, QU Y, CAI XB, et al. Effects of antiviral therapy on the reversal of liver fibrosis[J]. J Clin Hepatol, 2022, 38( 11): 2596- 2598. DOI: 10.3969/j.issn.1001-5256.2022.11.032.

    罗昕, 曲颖, 蔡晓波, 等. 抗病毒治疗对肝纤维化逆转的影响[J]. 临床肝胆病杂志, 2022, 38( 11): 2596- 2598. DOI: 10.3969/j.issn.1001-5256.2022.11.032.
    [9]
    MIAO L, JIA CH, CHEN HD, et al. Study on the factors influencing the reversal of liver fibrosis after the treatment of chronic hepatitis B with Entecavir received virological response[J]. Clin J Med Offic, 2024, 52( 2): 176- 179. DOI: 10.16680/j.1671-3826.2024.02.17.

    苗亮, 贾春辉, 陈寒冬, 等. 恩替卡韦治疗慢性乙型肝炎获得病毒学应答后肝纤维化逆转影响因素研究[J]. 临床军医杂志, 2024, 52( 2): 176- 179. DOI: 10.16680/j.1671-3826.2024.02.17.
    [10]
    LIU YN, LI MW, WANG LJ, et al. HBeAg-negative chronic HBV-infected individuals with normal alanine aminotransferase and an age of ≤30 years should be taken seriously when expanding anti-HBV treatment for chronic hepatitis B[J]. J Clin Hepatol, 2022, 38( 7): 1477- 1481. DOI: 10.3969/j.issn.1001-5256.2022.07.006.

    刘燕娜, 李明蔚, 王雷婕, 等. 扩大慢性乙型肝炎抗病毒治疗应重视ALT正常、年龄≤30岁的HBeAg阴性慢性HBV感染者[J]. 临床肝胆病杂志, 2022, 38( 7): 1477- 1481. DOI: 10.3969/j.issn.1001-5256.2022.07.006.
    [11]
    JURY TE. Easl international consensus conference on hepatitis B[J]. J Hepatol, 2003, 39( S1): 3- 25.
    [12]
    LOK A. Chronic hepatitis B[J]. Hepatology, 2001, 34( 6): 1225- 1241. DOI: 10.1053/jhep.2001.29401.
    [13]
    NONG CL, LONG TH, GUO Q. Characteristics of liver histology and the correlated index in patients with chronic hepatitis B and normal ALT levels[J]. J Pract Med, 2012, 28( 9): 1447- 1449. DOI: 10.3969/j.issn.1006-5725.2012.09.020.

    农村立, 龙腾河, 郭堑. ALT正常的慢性乙型肝炎肝组织学特点相关性无创指标分析[J]. 实用医学杂志, 2012, 28( 9): 1447- 1449. DOI: 10.3969/j.issn.1006-5725.2012.09.020.
    [14]
    YANG Q, LIU HE, YOU J, et al. Noninvasive diagnostic models for chronic hepatitis B liver fibrosis[J]. J Clin Hepatol, 2021, 37( 10): 2420- 2424. DOI: 10.3969/j.issn.1001-5256.2021.10.034.

    杨琴, 刘怀鄂, 游晶, 等. 慢性乙型肝炎肝纤维化的无创诊断模型[J]. 临床肝胆病杂志, 2021, 37( 10): 2420- 2424. DOI: 10.3969/j.issn.1001-5256.2021.10.034.
    [15]
    WEN Y, QU ZY, LU JN, et al. Value of liver-muscle signal intensity and serum markers in diagnosis of chronic hepatitis B liver fibrosis[J]. J Clin Hepatol, 2023, 39( 3): 573- 579. DOI: 10.3969/j.issn.1001-5256.2023.03.014.

    温雅, 屈兆宇, 鲁景楠, 等. 肝肌信号强度比及血清标志物对慢性乙型肝炎肝纤维化的诊断价值[J]. 临床肝胆病杂志, 2023, 39( 3): 573- 579. DOI: 10.3969/j.issn.1001-5256.2023.03.014.
    [16]
    LEE MH, CHEONG JY, UM SH, et al. Comparison of surrogate serum markers and transient elastography(fibroscan) for assessing cirrhosis in patients with chronic viral hepatitis[J]. Dig Dis Sci, 2010, 55( 12): 3552- 3560. DOI: 10.1007/s10620-010-1219-0.
    [17]
    ADINOLFI LE, GIORDANO MG, ANDREANA A, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis[J]. Br J Haematol, 2001, 113( 3): 590- 595. DOI: 10.1046/j.1365-2141.2001.02824.x.
    [18]
    CHEN YC, HSU CW, JENG WJ, et al. Advanced liver fibrosis is associated with necroinflammatory grade but not hepatic steatosis in chronic hepatitis B patients[J]. Dig Dis Sci, 2021, 66( 12): 4492- 4500. DOI: 10.1007/s10620-020-06761-x.
    [19]
    DENG Y, ZHANG S, JI D. Research progress on low-level viremia in chronic hepatitis B[J]. Infect Dis Inf, 2021, 34( 4): 342- 346. DOI: 10.3969/j.issn.1007-8134.2021.04.014.

    邓亚, 张珊, 纪冬. 慢性乙型肝炎低水平病毒血症的研究进展[J]. 传染病信息, 2021, 34( 4): 342- 346. DOI: 10.3969/j.issn.1007-8134.2021.04.014.
    [20]
    LI YD, FAN RS. Analysis of indications for antiviral therapy in chronic HBV patients with persistent normal level of alanine aminotransferase[J/CD]. Electron J Emerg Infect Dis, 2023, 8( 1): 44- 47. DOI: 10.19871/j.cnki.xfcrbzz.2023.01.009.

    李延东, 范荣山. 谷丙转氨酶持续正常的慢性乙型肝炎病毒感染者肝脏病理特征及预测因素[J/CD]. 新发传染病电子杂志, 2023, 8( 1): 44- 47. DOI: 10.19871/j.cnki.xfcrbzz.2023.01.009.
    [21]
    ZHENG M, CAI WM, WENG HL, et al. ROC curve in evaluation of serum fibrosis index for diagnosing hepatic fibrosis[J]. Chin J Infect Dis, 2002, 20( 4): 225- 228. DOI: 10.3760/j.issn: 1000-6680.2002.04.009.

    郑敏, 蔡卫民, 翁红雷, 等. ROC曲线评价血清纤维化指标对诊断肝纤维化的价值[J]. 中华传染病杂志, 2002, 20( 4): 225- 228. DOI: 10.3760/j.issn:1000-6680.2002.04.009.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (156) PDF downloads(20) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return